|
|
 |
|
Viewing report
|
|
|
|
Biotech Life Sciences: A 20/20 Vision to 2020
Burrill & Company, April 2008, Pages: 404
This document provides details of the contents and discussion in Biotech 2008 —Life Sciences: A 20/20 Vision for 2020, the 22nd annual report on the biotechnology industry from Burrill & Company. The publication examines the yearly performance of the biotech industry, makes predictions for the upcoming year, and provides insight how scientific; business and policy developments today will alter the healthcare landscape in 2020. One of the important accelerating trends reshaping the biotechnology industry is the emergence of personalized medicine.
Biotech 2008 Key Findings:
- The convergence of genomics, information technology, and nanotechnologies will radically alter every aspect of the healthcare system from the way companies develop and market drugs to the way individuals pay for and receive medical services.
- The biotech industry finished 2007 in good shape with a strong performance on the capital markets, which remained unpredictable all year long.
- The year saw 28 new biotech IPOs; financings and partnering deals collectively raising almost $45 billion for US companies. Although the industry had no difficulty raising money it had a tough time bringing new medicines to market with the prevailing safety-conscious attitude at the FDA taking its toll on new drug approvals.
- Demand for bio-ethanol, bio-diesel, and other alternative energy sources is driving technological innovation in the sector, especially in the production of cellulosic ethanol. Biotech crop acreage grew 12 percent and 12 million farmers around the world are benefiting from biotechnology.
- Internationally, biotechnology showed steady growth with China and India leading the way.
Predictions for 2020:
- Wal-Mart, plus other direct to consumer healthcare delivery institutions, will become the place to go for medical treatment.
- Your Blackberry will constantly monitor your health and alert your doctor of any problems.
- Nano-devices in the blood will diagnose and repair problems.
- Patients will carry their genome and health records on a smartcard.
- To be successful, companies will have to retool from being full-integrated to a virtually-integrated model
- People will be able to purchase organs off-the-shelf or even grow their own.
- Our ability to design and test new drugs using computer simulations (“in silico”), as well as new capabilities to test for harmful side effects on model systems assembled on computer chips (“labon-a-chip”) will continue to improve
- Implants and prostheses that mimic biological functions, restore critical functions to existing organs or tissues, or even augment those functions will begin to appear.
Customers who bought this item also bought
Biotech 2009-Life Sciences: Navigating the Sea Change
Companion Diagnostics in Personalized Medicine and Cancer Therapy
Personalized Medicine - Scientific and Commercial Aspects
Biomarkers and Tests for Pharma/ Biotech R&D � Companies Products and WW Market, 2006-2011
Merger and Acquisition Agreements in Pharma, Biotech and Diagnostics, 2nd edition
Systems Biology in Biotech and Pharma: A New Paradigm for Innovation
It's All About the Biomarkers: How 2008's Biomarker-Based Partnering Is Driving Personalized Medicine
China Biotech 2008
Dealmaking and Business Strategies in the Age of Personalized Medicine
Personalized Medicine
Oncology Partnering Agreements in Pharma, Biotech and Diagnostics
Beyond The Blockbuster Drug: Strategies For Nichebuster Drugs, Targeted Therapies and Personalized Medicine.
|
|
|
|
